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A Strategic Plan for the Elimination of 
Tuberculosis in the United States
Message to the Readers of Morbidity and Mortality Weekly Report
I am pleased to provide you with "A Strategic Plan for the Elimination of 
Tuberculosis in the United States" describing actions necessary to achieve the goal 
by the year 2010, with an interim target of a case rate of 3.5 per 100,000 population by 
the year 2000. At a national conference in 1984, Dr. James 0. Mason, then Director of 
the Centers for Disease Control, challenged the public health community to develop 
a strategy to eliminate tuberculosis from the United States. This plan was developed 
by the Centers for Disease Control/Department of Health and Human Services' 
Advisory Committee for Elimination of Tuberculosis. Many experts from both within 
and outside the Department played a significant role in its development. We are 
grateful to all those who participated in the process.
I am pleased to report that the House of Delegates of the American Medical 
Association and the Governing Council of the American Public Health Association 
have passed resolutions in support of the plan, and the American Lung Association 
and the American College of Preventive Medicine have also endorsed the goal. We 
thank these organizations for their support and anticipate that other organizations will 
take similar actions in the near future.
We must commit ourselves to the objective of eliminating tuberculosis and making 
that objective widely known so others can join in this effort. The Centers for Disease 
Control is identifying activities for short- and long-term implementation. The plan is 
being distributed to a wide variety of public and private organizations with the 
recommendation that they take similar action.
The goal of eliminating this disease and its tragic consequences from the United 
States is achievable, and we believe it will be broadly supported by all sectors of our 
society.
Walter R. Dowdle, Ph.D.
Acting Director 
Centers for Disease Control

Contents
Introduction...................................................................................................................... 1
Background Information.................................................................................................. 2
Step 1 -  More Effective Use of Existing Prevention and Control Methods............. 3
Improving Surveillance................................................................................................4
Improving Case Prevention................................................ ,.......................................5
Improving Disease Containment................................................................................. 7
Program Assessment and Evaluation......................................................................... 8
Conclusion.....................................................................................................................8
Step 2 — Development and Evaluation of New Prevention,
Diagnostic, and Treatment Technologies..................................................................9
Improving Methods for Preventing Disease in Infected Persons............................. 9
Improving Methods for Identifying Infected Persons at Risk of Disease............... 12
Improving Methods for Preventing Infection or the Establishment of 
Infection in Various Body Sites..............................................................................13
Improving Methods for Treating Disease.................................................................14
Improving Methods for Diagnosing Disease............................................................14
Conclusion................................................................................................................... 15
Step 3 -  Technology Assessment and Transfer........................................................15
Technology Assessment and Transfer in General...................................................15
Special Technology Transfer Issues..........................................................................18
Transfer of Communication Technologies................................................................20
Conclusion...................................................................................................................20
References......................................................     20
Appendix: Planning Assumptions............................................................................... 23
April 21, 1989 MMWR iii
Vol. 38 / No. S-3 MMWR 1
Nothing will ever be attempted if all 
possible objections must be first overcome.
— Samuel Johnson
INTRODUCTION
In 1987, the Secretary of the U.S. Department of Health and Human Services 
established an Advisory Committee for Elimination of Tuberculosis* to provide 
recommendations for developing new technology, applying prevention and control 
methods, and managing state and local tuberculosis programs targeted at eliminat­
ing tuberculosis as a public health problem. After review and feedback from 
numerous interested people and organizations, this plan was completed.
The committee urges the nation to establish the goal o f tuberculosis elimination 
(a case rate o f less than one per million population) by the year 2010, with an interim 
target o f a case rate o f 3.5 per 100,000 population by the year 2000. The U.S. case rate 
for 1987 was 9.3 per 100,000 (1).
Three factors make this a realistic goal: 1) tuberculosis is retreating into geograph­
ically and demographically defined pockets; 2) biotechnology now has the potential 
for generating better diagnostic, treatment, and prevention modalities; and 3) 
computer, telecommunications, and other technologies can enhance technology 
transfer. Therefore, a three-step plan of action was developed:
1. more effective use of existing prevention and control methods, especially in 
high-risk populations
2. the development and evaluation of new technologies for treatment, diagnosis, 
and prevention
3. the rapid assessment and transfer of newly developed technologies into clinical 
and public health practice
The committee brings this plan to the attention of the medical community and the 
public to stimulate positive, constructive discussion and action, to increase the 
public's level of awareness of tuberculosis, and to encourage a commitment to the 
elimination of tuberculosis. In the past, the United States has spent hundreds of 
millions of dollars annually on tuberculosis treatment and control activities. Unless 
alternative action is taken, large and unnecessary expenditures will continue indefi­
nitely. Expenditures on tuberculosis treatment may increase over the next few years 
because of high morbidity rates among people infected with the human immunode­
ficiency virus (HIV), the homeless, the foreign-born, the elderly, and various minority 
groups. Furthermore, tuberculosis has the potential for spreading more widely in the 
community.
* The Advisory Committee membership is as follows: Dr. William C. Banton II, Dr. George W. 
Comstock, Chairman, Dr. James L. Hadler, Mr. Anthony P. Najera, Ms. Carol J. Pozsik, Dr. Robert 
J. Reza, Dr. John A. Sbarbaro, Dr. Margaret H.D. Smith, Dr. William W. Stead, Dr. Patricia N. 
Whitley; Ex officio members: Dr. William A. Robinson (HRSA), Dr. Darrel D. Gwinn (NIH), Dr. 
Sotiros D. Chaparas (FDA), Dr. Bruce Tempest (IHS); Liaison members: Mr. Shane McDermott 
(ALA), Dr. Shirley Kellie (AMA), Dr. Dixie E. Snider, Jr., Executive Secretary.
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The mission of all tuberculosis control programs should now be to eliminate this 
disease by the year 2010. Strategies for eliminating tuberculosis are set out in this 
document. These strategies are based on the needs and responsibilites of the various 
groups of people involved in this effort (Appendix). The committee realizes the task 
will not be an easy one; it will require considerable commitment at all levels. The 
challenge to carry out this plan is a test of our willingness and ability as a society to 
respond to a very serious health problem that disproportionately affects its disen­
franchised members. A great nation such as ours can carry out this plan. It is time to 
commit to a tuberculosis-free society!
BACKGROUND INFORMATION
Tuberculosis is a communicable disease caused by bacteria (Mycobacterium 
tuberculosis complex) that are usually spread from person to person through the air. 
When people with tuberculosis of the respiratory tract cough, airborne infectious 
particles are produced. If these bacteria are inhaled by other people, they cause an 
infection that spreads throughout the body. Most individuals who become infected do 
not develop a clinical illness because the body's immune system brings the infection 
under control; however, infected people do develop a positive reaction to a tuberculin 
skin test. The infection can persist for years, perhaps for life, and infected persons 
remain at risk of developing disease at any time, especially if the immune system 
becomes impaired. Although the disease usually affects the lung, it can occur at 
virtually any site in the body.
Despite the great strides that have been made in the control of tuberculosis, the 
disease continues to be a public health problem in the United States. There remain 
isolated and potentially dangerous enclaves of this preventable, but frequently severe 
and occasionally fatal, disease. If more aggressive action is not taken, thousands of 
preventable cases and deaths will continue to occur in the United States each year 
until well into the next century. This document has been prepared to identify the steps 
necessary to eliminate tuberculosis.
Ongoing analyses of tuberculosis morbidity data continue to identify the magni­
tude and extent of the problem. These data have important implications for the 
control and elimination of tuberculosis in the United States.
From 1953 through 1984, the number of tuberculosis cases reported decreased an 
average of 5% annually (7). However, in 1985, the number of tuberculosis cases 
remained stable and, in 1986, cases increased by 2.6% (2,3). This increase was, at 
least in part, caused by the occurrence of tuberculosis among persons infected with 
HIV (2-4). HIV infection appears to have increased the incidence of tuberculosis by 
causing immunosuppression, which allows latent tuberculous infection to progress 
to clinically apparent disease. Therefore, tuberculosis screening and prevention 
efforts will need to be targeted to persons with, or at risk for, HIV infection.
Although tuberculosis case rates have progressively declined for all races over the 
past two decades, the decrease has been much less among nonwhites than among 
whites. Nearly two-thirds of cases now occur among blacks, Hispanics, Asians, and 
Native Americans (5-10). Although specific data are not available, the higher risk in 
these minority populations may be related primarily to socioeconomic conditions,
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such as poor housing and nutrition. Thus, prevention and control strategies should be 
formulated in consultation with, and targeted toward, these high-risk minority 
populations.
Tuberculosis is also common among immigrants, refugees, and migrant workers 
from countries where the disease is prevalent (10). In these patients, organisms 
responsible for disease are frequently resistant to commonly used antituberculosis 
drugs, especially isoniazid (INH). If not recognized and managed appropriately, 
drug-resistant disease and infection may lead to failure of treatment or preventive 
measures. Almost half the cases among immigrant Asians occur within the first 2 
years of arrival in the United States. Specific control efforts should thus be directed at 
recent immigrants before or shortly after their arrival. Over two-thirds of cases in 
foreign-born persons occur in those who are less than 35 years old at the time of 
arrival in the United States (10). These cases are potentially preventable.
More than 80% of childhood cases occur in minority groups. Childhood cases are 
geographically focal. Less than 12% (363) of U.S. counties reported one or more 
tuberculosis cases among children in 1986 (CDC unpublished data). Using childhood 
cases as sentinel health events, health departments can target certain populations for 
preventive intervention.
Among all racial and ethnic groups and both sexes, tuberculosis case rates are 
highest among the elderly. Although case rates are higher among the 5% of the 
elderly living in nursing homes, the majority of cases occur among 95% of the elderly 
who live in the community.
Good epidemiologic surveillance data are essential for an effective tuberculosis- 
elimination effort. These data target the populations and geographic areas experi­
encing the problem and provide clues as to how to deal with it. Additional data are 
needed to define the extent to which correctional institution populations, homeless 
people, lower socioeconomic groups, and others are at increased risk. While analyses 
of national data are useful, analyses of state and local data will be even more 
important for targeting elimination efforts.
STEP 1 -  MORE EFFECTIVE USE OF EXISTING PREVENTION 
AND CONTROL METHODS
The emphasis in this section is on currently available prevention and control 
strategies not being fully utilized and on new strategies using existing technology. 
Although new technologies will be needed to eliminate tuberculosis (see Step 2), 
much can be achieved through efforts to improve existing tuberculosis control 
programs. Detailed recommendations for diagnosis, prevention, treatment, and 
program management are included in various American Thoracic Society and CDC 
statements and in CDC's Tuberculosis Policy Manual. Our recommendations are quite 
general and will need to be adapted at the state, community, and individual level. 
They are meant to serve as guidelines and not to establish rigid standards of practice 
or to discourage creativity and innovation.
Priorities for Step 1 include adequate and appropriate treatment for all persons 
with tuberculosis, identification of high-risk population groups within each geo­
graphic area, and the use of preventive treatment in the appropriate members of
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these groups. Strategies are organized in terms of surveillance, prevention of disease 
and infection, containment of disease, and program evaluation and assessment.
Improving Surveillance
The identification and reporting of tuberculosis cases, suspected cases, and 
contacts is often slow or incomplete, thus delaying treatment and preventive 
intervention. Some cases are not diagnosed or reported, and contact investigation is 
not done. This is more likely to occur among the poor, the elderly, the homeless, drug 
users, and prisoners.
By January 1, 1991, systems should be in place to assure that: 1) all persons with 
signs and symptoms suggestive of tuberculosis receive an appropriate diagnostic 
evaluation within 2 weeks of initial contact with a health-care provider; 2) suspected 
or diagnosed cases are reported to health departments within 3 days of the time the 
diagnosis is made or suspected, or a positive laboratory result is obtained, so that 
contacts can be identified and examined; 3) active population-specific casefinding, 
screening, and preventive intervention programs are established and maintained by 
health departments; and 4) achievement of the above objectives is measured and 
assessed.
Methods
1. Health departments, medical and nursing schools, schools of public health, 
volunteer agencies, professional societies, and minority advocacy groups should 
educate health-care providers and high-risk groups in the community about the 
signs and symptoms of tuberculosis and the methods of diagnosis, treatment, 
and prevention.
2. To speed up case reporting and make it easier for health-care providers to report, 
health departments should initiate telephone reporting systems for reportable 
infectious diseases, including tuberculosis, as a replacement or supplement to 
written notification. This system should include a telephone answering machine 
to record off-hour reports. Computer-to-computer reporting using telecommuni­
cations systems should be developed to further improve surveillance.
3. Physician, laboratory, and hospital reporting of cases to health departments 
should continue. Pharmacy reporting of persons who receive a supply of 
antituberculosis drugs should be undertaken on a pilot basis to determine 
whether additional cases are found.
4. Health department staffs should routinely monitor the time between the diagno­
sis of tuberculosis and the date the case is reported to the health department. 
Delays of more than 3 days should be investigated and action taken to prevent 
similar delays in the future.
5. Health department staff should conduct periodic reviews of selected records 
systems (e.g., laboratory reports, pharmacy reports, AIDS registries, and death 
certificates) to validate the surveillance system and to detect any failures to report 
cases.
6. Clinicians and public health officials should identify groups of people in the 
community among whom tuberculosis and transmission of infection are occur­
ring. This may require collection and analysis of data (e.g., residence, occupation, 
socioeconomic-status indicators, and HIV-antibody status) not now included on
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the individual case-report form. These data are necessary to identify high-risk 
populations and areas in which active casefinding and preventive intervention 
programs should be conducted. Members of high-risk groups and their health­
care providers should be apptised of the problem and involved in the design, 
implementation, and evaluation of casefinding and prevention programs.
Improving Case Prevention
Preventable tuberculosis cases continue to occur in the United States. By defini­
tion, preventable cases include all those for whom one or more of the currently 
recommended interventions should have been utilized but were not. These interven­
tions include contact identification and examination, preventive therapy for infection, 
prompt diagnosis of disease, prompt reporting, isolation of persons with suspected 
and diagnosed tuberculosis, adequate ventilation of buildings, the use of ultraviolet 
lights in high-risk areas of buildings, chemotherapy for disease, and directly observed 
therapy. Some of these interventions (e.g., isolation) are designed to prevent 
transmission of infection among residents and staff of high-risk institutions such as 
hospitals, nursing homes, correctional institutions, and shelters for the homeless. 
Other interventions (e.g., preventive therapy) are designed to prevent disease among 
those already infected. INH preventive therapy reduces the risk of tuberculosis by 
more than 90% among persons who complete a full course of treatment.
To prevent infection among persons potentially exposed to an infectious case of 
tuberculosis and to prevent tuberculosis among contacts and other infected persons 
for whom preventive therapy is recommended, the following methods should be 
implemented by January 1, 1991.
Methods
1. All U.S. residents should have the results of at least one tuberculin skin test in 
their medical records, and those whose test result is positive should be evaluated 
and counseled regarding their risk of developing tuberculosis.
2. Each health department should assess the prevalence, incidence, and socio­
demographic characteristics of cases and infected persons in the community. On 
the basis of these data, health departments should initiate tuberculin screening 
programs specifically targeted to each community's high-risk groups. Screening 
may be done to identify suspects, undiagnosed cases, diagnosed cases lost to 
follow-up, and infected persons in need of preventive therapy. At a minimum, 
health departments should ensure that such programs are extended to persons 
with symptoms compatible with tuberculosis, all foreign-born persons (and their
. families) from high-prevalence areas, high-risk minority groups, the homeless, 
migrant workers, persons being admitted to nursing homes, people entering 
correctional institutions, and people known to be infected with HIV. In addition to 
their prevention value, screening programs have the potential for providing 
publicity and generating goodwill for the tuberculosis program.
3. Tuberculin skin-testing programs should be conducted annually among the staffs 
of tuberculosis clinics, mycobacteriology laboratories, shelters for the homeless, 
nursing homes, substance-abuse treatment centers, dialysis units, and correc­
tional institutions. The staffs of hospitals, mental institutions, and home health­
care agencies should be tested annually if the prevalence of infection exceeds 5%.
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4. Consideration should be given to installing and properly maintaining ultraviolet 
lights in high-risk facilities such as jails, prisons, and shelters for the homeless 
(10-13).
5. Hospitals that admit untreated tuberculosis patients or persons suspected of 
having tuberculosis should have proper facilities and procedures for instituting 
respiratory isolation.
6. Consideration should be given to routinely obtaining sputum for mycobacterial 
smear and culture from symptomatic nursing home residents thought to have a 
lower respiratory infection.
7. Tuberculosis patients and persons suspected of having tuberculosis should be 
interviewed within 3 days after the health department receives the case report by 
a person who has had specific training in contact interviewing.
8. Close contacts should be examined within 7 days after the index case is 
diagnosed.
9. Infected contacts should be placed on preventive therapy if there is no evidence 
of clinical disease.
10. A child whose skin test shows no evidence of infection and who is a close contact 
of someone with infectious tuberculosis should be placed on preventive therapy 
until repeat skin testing (3 months after contact is broken) confirms the absence 
of infection.
11. All persons identified with HIV infection should be tuberculin tested. Those with 
positive tuberculin reactions or a history of a positive tuberculin reaction (without 
active disease) should be considered for preventive therapy, regardless of age.
12. All other recognized high-risk, infected persons should be considered for preven­
tive therapy regardless of age. This includes recently infected persons (i.e., 
persons who had negative skin-test results who have converted to positive test 
results), persons with chest radiographic findings consistent with past tubercu­
losis, and those with medical risk factors known to substantially increase the risk 
of tuberculosis (e.g., silicosis, below ideal body weight, gastrectomy, immuno­
suppressive therapy).
13. Screening of refugees, immigrants, and entrants from high-incidence countries 
should be continued and infectious persons with tuberculosis excluded until they 
become noninfectious. These groups should also be screened for tuberculous 
infection (without disease). Unless contraindicated, those with infection (without 
disease) should be started on preventive therapy either before, or within 2 
months after, their entry into the United States.
14. Infected persons placed on preventive therapy should complete a full course of 
treatment.
15. Twice-weekly, directly observed preventive therapy should be used whenever 
necessary to ensure compliance, especially if the number of persons on daily 
supervised preventive therapy would overextend the personnel resources as­
signed to the program.
16. Patients on INH preventive therapy must be carefully monitored on a monthly 
basis for compliance and signs and symptoms of toxicity. Spot testing of urine for 
INH metabolites is highly recommended when therapy cannot be observed 
directly. If signs or symptoms of toxicity appear, therapy should be stopped
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immediately and the patient reevaluated. No more than a 1-month supply of 
medicine should be dispensed at any visit.
17. BCG vaccine should be considered in those rare situations in which other control 
measures cannot be applied and uninfected children are exposed to infectious 
persons who remain untreated.
Improving Disease Containment
Many tuberculosis patients do not complete a recommended course of therapy. 
More than 25% of sputum-positive patients are not known to have converted from 
positive to negative sputum culture within 6 months. In addition, almost 12% of 
patients are not known to be currently receiving therapy, and more than 17% of 
tuberculosis patients do not take their medication continuously (74 ).
Beginning immediately, all patients with tuberculosis should complete treatment 
with an appropriate regimen.
Methods
1. For each new case of tuberculosis in the United States, a specific health 
department employee should be assigned the responsibility and held account­
able for ensuring the education of the patient about tuberculosis and its treat­
ment, ensuring continuity of therapy, and ensuring that contacts are examined. 
The health-care worker should visit the patient within 3 days of diagnosis to 
identify contacts and possible problems related to compliance with therapy.
2. For each new infectious case, a specific treatment and monitoring plan should be 
developed within 4 days of diagnosis. This plan should include drugs to be used 
(doses, duration, and frequency of administration), assessment of toxicity, and 
methods to be used to assess and ensure compliance.
3. Appropriate antituberculosis drugs, laboratory services, contact investigations, 
contact examinations, and other necessary services should be provided to 
patients by health departments without regard to the patients' ability to pay.
4. Incentives may be necessary to enhance compliance. To be most effective, 
incentives should be tailored to the individual needs and desires of the patients. 
An incentive may be as simple as offering a cup of coffee and talking with a 
patient while he or she is waiting in the clinic, or as complex as providing food 
and housing for a homeless patient. Particular attention must be given to 
ensuring that patients have transportation to the clinic.
5. Twice-weekly, directly observed therapy should be used whenever needed. 
Specific funding for outreach staff should be encouraged at the federal, state, and 
local level. Alternatives to federally funded outreach staff might include, for 
example, appropriately instructed home health-care workers or maternal and 
child health staff to supervise therapy.
6. Quarantine measures, including temporary institutionalization, should be used in 
those instances when an infectious patient refuses to comply with self- 
administered or directly observed therapy. State and local laws and regulations 
should be modernized to facilitate the cure of persons with infectious tuberculo­
sis. For example, court-ordered compliance with directly observed therapy 
should be available.
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Program Assessment and Evaluation
In many areas, there is incomplete assessment of community tuberculosis control 
problems and inadequate evaluation of community prevention and control efforts. As 
a result, programs do not function as effectively and efficiently as they should.
By January 1, 1991, a system should be in place to achieve an ongoing, effective 
assessment of the tuberculosis problem and evaluation of the activities being 
performed at all levels for the control and elimination of tuberculosis.
Methods
1. The Federal Government and state and large metropolitan health departments 
should annually evaluate their progress toward the elimination of tuberculosis. 
This evaluation should include an analysis of morbidity and mortality data, case 
reporting, case finding, treatment, and prevention activities. Annual evaluations 
could be done in collaboration with interested constituencies such as lung 
associations, minority organizations, and professional societies. Regional meet­
ings to share information among states are encouraged.
2. Expert assessment should be conducted annually for local health departments by 
the state, CDC, or the American Lung Association/American Thoracic Society and 
for state health departments by CDC or the American Lung Association/American 
Thoracic Society. A similar assessment of federal tuberculosis prevention and 
control activities should be conducted by the CDC Advisory Committee for 
Elimination of Tuberculosis or other outside consultants.
3. Priority for continued federal funding of state and local programs should be, at 
least in part, contingent upon improved program performance and productive 
activities in high-risk populations.
4. A prototype computerized record system should be developed by CDC for use by 
local programs for case reporting, patient management, and program assess­
ment. CDC should provide microcomputers, with appropriate software and 
training, to state and major city health department tuberculosis control programs 
in high-incidence areas.
5. Each state and major metropolitan area should develop and publish an annual 
community tuberculosis summary and program plan (including objectives, meth­
ods, a discussion of program progress or failure, and corrective action needed).
6. Health departments should review each new tuberculosis case and each death 
from tuberculosis to determine if the case or death could have been prevented 
had the American Thoracic Society/CDC recommendations been followed. Based 
on these reviews, new policies should be developed and implemented to reduce 
the number of preventable cases.
Conclusion
Implementation of Step 1 of this plan will require strong commitment at the 
national, state, and community levels. State and local tuberculosis advisory groups, 
with broad representation from public, private, and voluntary medical groups, should 
develop and help implement Step 1 strategies appropriate for the state or community.
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STEP 2 -  DEVELOPMENT AND EVALUATION OF NEW 
PREVENTION, DIAGNOSTIC, AND TREATMENT 
TECHNOLOGIES
In June 1985, CDC, the National Institutes of Health, the American Thoracic 
Society, and the Pittsfield Antituberculosis Association cosponsored a conference in 
Pittsfield, Massachusetts. The objective of this conference was to identify areas for 
research that would lead to improved technologies for eliminating tuberculosis from 
the United States. The complete report of this conference was published in the 
August 1986 issue of the American Review o f Respiratory Disease (15). Conse­
quently, only selected priority projects are mentioned here.
The five headings under which research projects and activities are listed represent 
critical objectives for eliminating tuberculosis. They are presented in priority order. 
These projects should also be regarded in terms of type of research, i.e., basic, 
applied, and epidemiologic/operational (Table 1). Basic research is intended to obtain 
a better understanding of structure, processes, and mechanisms of tuberculosis. 
While the findings from this research can often be applied for some clinical or public 
health purpose, basic research does not proceed with a specific application in mind. 
As already implied, applied research has as its goal the application of knowledge to 
the solution of a particular clinical or public health problem. Epidemiologic studies 
are designed to assess the magnitude, distribution, and determinants of disease in a 
population. Operational research studies assess the actual impact of interventions on 
health outcomes in the population.
Improving Methods for Preventing Disease in Infected Persons
The vast majority of new cases of tuberculosis arise in persons who have had a 
latent period of infection. The most critical element in tuberculosis elimination is the 
detection and treatment o f infected persons before disease emerges. At present, INH 
is usually administered for 6-12 months for preventive therapy. However, this 
approach has major deficiencies. These include the expense of treating and monitor­
ing patients for such a long time, noncompliance with preventive therapy of long 
duration, and the occurrence of drug toxicity, especially hepatotoxicity.
The first-priority objective of Step 2 is to develop shorter, safer, more effective and 
more economical means of preventing the emergence of clinical disease from the 
infected state.
Methods
Areas of research to be pursued are as follows:
1. A drug that is more effective and less toxic than INH should be identified. This will 
require research at several levels.
a. The mechanisms by which current antituberculosis drugs act are poorly 
understood. Consequently, studies of microbial metabolism, with identification 
of target sites for drug activity, should be conducted to develop new ap­
proaches to preventive therapy.
b. In vitro models of drug efficacy, especially those allowing assessment of the 
interactions of drug, phagocyte, and organism, should be developed to help 
select drugs for in vivo studies.
TABLE 1. Improving Methods for Prevention, Diagnostic, and Treatment Technologies (Summary Sheet)
Kind of I. Preventing disease il. Identifying infected
research in infected persons_________ persons at risk of disease III. Treating disease__________ IV. Preventing infection V. Diagnoses of disease
Basic 1. Identify target sites 
of drug action; develop 
new therapeutic approaches.
2. Develop models to assess 
interaction of drug, host, 
and organism.
3. Develop animal models 
for preventive therapy.
4. Study mechanisms of 
INH-hepatitis.
5. Develop postinfection 
vaccines to boost immunity.
6. Boost host immunity to 
destroy intracellular 
bacilli.
1. Study differences in 
T-cell memory between 
infected persons who do 
or do not develop active 
disease.
2. Look for genetic 
differences between 
infected persons who do 
or do not develop disease.
3. Characterize genes that 
code for specific epitopes 
of mycobacteria.
1. Define target enzymes 
for anti-TB drugs; design 
new drugs or modify 
existing ones with 
higher affinity for 
target sites.
2. Improve knowledge of 
drug transport mechanisms 
so drugs can be developed/ 
modified to facilitate 
uptake into intracellular 
environment of macrophages.
3. Identify pharamcologic 
agents that activate 
T-cells/macrophages.
4. Enhance microbicidal 
activity of in vitro- 
maintained phagocytes by 
manipulation of micro­
environments.
1. Pursue studies on 
tubercle bacilli relevant 
to infectivity and 
pathogenicity.
2. Compare uptake, micro­
environmental distribution, 
and replication of 
avirulent, attenuated,
and virulent tubercle 
bacilli.
3. Determine host factors 
(HLA phenotype) that 
affect susceptibility and 
resistance to TB 
infection.
4. Develop nonliving, non- 
allergenic vaccine to 
prevent establishment of 
infection. This research 
should include efforts to 
(a) identify epitopes of
M. tuberculosis responsible 
for protection and produce 
same by genetic 
engineering; (b) maximize 
protection by different 
immunization methods or 
regimens; (c) develop bio­
logic response modifiers 
to enhance protection; and 
(d) identify populations 
in which vaccine could be 
tested.
1. Search for genus- and 
species-specific epitopes.
2. Develop assays for 
diagnostic materials 
produced by lymphocytes 
or macrophages of diseased 
host; also investigate 
T-lymphocyte antigen 
receptor.
M
M
W
R
 
April 21, 1989
TABLE 1. Improving Methods for Prevention, Diagnostic, and Treatment Technologies (Summary Sheet) — Continued
Kind of I. Preventing disease II.Identifying infected
research______ in infected persons__________persons at risk of disease III. Treating disease________IV. Preventing infection V. Disgnoses of disease
Applied 1. Develop animal model to
evaluate different single 
or combination drugs for 
preventive therapy.
2. Develop bactericidal 
INH congeners that are 
not hepatotoxic.
3. Develop cytoprotective 
agents to neutralize INH 
toxicity.
4. Develop long-acting depot 
forms of anti-TB drugs.
5. Develop and evaluate 
postinfection vaccines 
for TB.
1. Evaluate antimyco- 
bacterial activity of all 
new antimicrobials, and 
test combinations for 
synergy.
2. Seek bactericidal 
agents that affect myco­
bacteria in all metabolic 
states.
3. Study pharmacologic 
agents that activate 
T-cells and macrophages.
4. Investigate techniques 
that enhance microbicidal 
activity of phagocytes.
5. Investigate improved 
drug-delivery systems.
1. Define better methods 
for air disinfection.
2. Evaluate new vaccines 
shown in experimental 
models to prevent 
infection.
1. Evaluate DNA probes 
specific for
M. tuberculosis.
2. Produce and evaluate 
genus- and species-specific 
monoclonal antibodies for 
rapid identification of
M. tuberculosis.
3. Use probes or mono­
clonal antibodies to 
detect, in clinical 
specimens, either intact 
mycobacteria or their 
antigens that would be 
diagnostic of disease.
Epidemiologic/ 1. Compare alternative to 
Operational daily INH preventive 
therapy.
2. Determine risk factors 
that precipitate INH- 
hepatitis.
3. Identify "risk factors" 
to measure benefits of 
preventive therapy.
1. Assess risk of tubercu­
losis among those infected 
with both M. tuberculosis 
and HIV.
2. Conduct prospective 
studies to investigate 
risk factors for active 
disease, e.g., socio­
economic status, weight, 
nutrition, environment.
1. Investigate B-lactams, 
long-acting sulfones and 
sulfonamides, rifamycins, 
and 4-quinolones.
2. Identify compliance 
enhancers or incentives 
and develop tests to 
recognize people who 
best respond to them.
1. Define methods that 
identify groups or 
individuals at risk of 
infection.
2. Examine patient 
characteristics that 
influence infectiousness.
1. Evaluate diagnostic 
methods under field 
conditions.
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c. Animal models for studying preventive therapy of latent infection should be 
developed.
d. Based on present and developing knowledge, candidate drugs should be 
evaluated in high-risk groups both in the United States and in other countries.
2. Alternatives to daily INH preventive therapy regimens (e.g., multi-drug regimens, 
rifampin alone, twice-weekly INH) should be evaluated.
3. Because hepatotoxicity is a major limitation to the use of INH preventive therapy, 
research efforts should be encouraged that a) contribute to the understanding of 
the mechanisms of INH-hepatitis, b) contribute to the understanding of the 
mechanism by which INH acts, which will in turn facilitate the development of 
congeners that retain antimicrobial potency while eliminating sites of hepatotoxic 
potential, c) investigate the cytoprotective effects of agents that may block or 
interfere with the toxic effects of INH, and d) identify more specific risk factors, 
other than age, for the development of INH-hepatitis.
4. High priority should be given to the development of a postinfection vaccine to 
boost the specific immune response.
5. Modification of the host immune response to M. tuberculosis infection should be 
evaluated as a supplement to chemoprophylaxis to boost the immune response 
and increase destruction of intracellular parasites.
Improving Methods for Identifying Infected Persons at Risk of Disease
The use of the Mantoux test with tuberculin, purified protein derivative (PPD), to 
identify persons infected with M. tuberculosis is well established. However, the test 
suffers from a lack of sensitivity and specificity. In addition, the test is difficult to 
interpret in serial testing programs because of the "booster effect." In conjunction 
with the skin test, epidemiologic factors and patient characteristics have been used to 
identify persons at high risk of developing disease. The risk of developing clinically 
apparent tuberculosis is increased by recently acquired infection, young adulthood, 
leanness, and disease states in which T-lymphocyte function is disturbed (16). Despite 
this knowledge, we currently have a very limited ability to predict which infected 
persons are most likely to develop disease.
Preventive therapy would be a much more efficient intervention for reducing 
tuberculosis morbidity if there were better methods for identifying persons infected 
with M. tuberculosis (i.e., those who are at risk of developing disease). Ideally, a test 
is needed that is capable of specifically differentiating those who harbor living 
tubercle bacilli from those who do not.
Methods
1. Genes that code for species-specific epitopes of mycobacteria should be identi­
fied and characterized. This should permit amino acid analysis and synthesis of 
epitopes which may be useful for serologic or skin-test diagnosis.
2. T-lymphocytes are the key responding cellular elements of the immune response 
to M. tuberculosis. These cells should be studied to identify subpopulations of 
T-lymphocytes that influence progression or containment of infection.
3. Genetic differences, such as those related to histocompatibility complex antigens, 
between infected persons who develop disease and those who do not should be 
sought.
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4. The absolute and relative risk of disease among persons infected with both the 
tubercle bacillus and HIV should be determined.
5. Socioeconomic status, immunodeficiency status, stress (both physical and psy­
chological), body weight, nutrition, and environmental factors (e.g., incarceration, 
sunlight, ventilation) should be investigated as risk factors in prospective or 
case-control studies.
Improving Methods for Preventing Infection or the Establishment of 
Infection in Various Body Sites
Transmission of M. tuberculosis infection usually occurs via the airborne route. 
Current methods for preventing the transmission of infection to uninfected persons 
include early identification, isolation, and treatment of infectious source cases; 
environmental control to reduce the number of airborne infectious particles through 
the use of nonrecirculated ventilation to the outdoors and ultraviolet light; and drug 
therapy of uninfected persons who are exposed to infection sources. Vaccination with 
BCG does not prevent infection but may limit the spread and complications of the 
disease (77). Each of these measures has certain drawbacks, and transmission of 
infection is still occurring at unacceptable levels. Therefore, more reliable methods 
are needed for preventing infection and for limiting its spread within the body.
Methods
1. Source case factors
a. Patient characteristics that influence infectiousness should be thoroughly 
examined.
2. Environment- or bacteria-oriented factors
a. Research on systems for better air disinfection should be conducted.
b. Studies that would increase our understanding of the pathogenicity of M. 
tuberculosis and how this may affect infectivity and virulence should be 
pursued.
3. Studies on the host's native resistance
a. Host factors (e.g., nutritional state, genetic makeup, level of stress) that affect 
susceptibility and resistance to tuberculous infection should be identified.
b. More refined epidemiologic methods for identifying groups and persons at risk 
of becoming infected should be investigated.
c. In vitro studies of the immune and nonimmune macrophage's ability to handle 
virulent and avirulent strains of M. tuberculosis should be undertaken to 
identify factors that affect the macrophage's ability to destroy these organisms.
4. Vaccination
a. Studies to identify protective immunogenic component antigens of M. tuber­
culosis should be undertaken and procedures for large-scale production, 
purification, and synthesis of these antigens should be developed.
b. Different immunization techniques, with and without biological response 
modifiers, should be evaluated.
5. Populations in which a vaccine trial could be carried out should be identified.
6. Studies should be done to determine if persons or groups differ with regard to 
infectibility and whether this could be altered in some way.
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Current drug regimens are effective, well tolerated, and can be given with minimal 
effects on the patient's mode of living. Nevertheless, major problems remain. With 
current drugs, a minimum of 6 months of multi-drug therapy is necessary to achieve 
a high probability of cure (18). There are at least four obstacles to achieving a cure: 
1) the failure of patients to comply with regimens of long duration, 2) drug-resistant 
organisms, 3) adverse reactions that require interruption and modification of the 
original, and usually optimal, drug regimen, and 4) the cost of the most effective 
regimens.
The following steps should be taken to develop more effective approaches to 
therapy for tuberculosis.
Methods
1. All new antimicrobial agents should be routinely evaluated in vitro for antimy- 
cobacterial activity. In addition, drug combinations should be examined for 
synergy.
2. Classes of compounds that should receive high priority in the search for better 
treatment regimens are beta-lactam compounds, long-acting sulfones and sulfo­
namides, rifamycins, and 4-quinolones.
3. Improved delivery systems-including longer acting drug-release systems, such 
as injectable suspensions, implantable rods, and membrane-enclosed drugs- 
should be sought.
4. Research to define enzyme targets for antituberculosis drugs should be carried 
out. This information will facilitate the design of new drugs with higher affinity for 
these target enzymes, or indicate rational modifications of existing drugs for the 
same purpose. High priority should be placed on finding rapidly effective, 
bactericidal agents that affect mycobacteria in all metabolic states.
5. Because mycobacteria within macrophages are not readily accessible to many 
drugs, a knowledge of drug transport mechanisms should be acquired to allow 
modification of drugs to facilitate uptake.
6. Pharmacologic agents that activate T-lymphocytes and macrophages should be 
identified and evaluated in patients with mycobacterial diseases.
7. Manipulation of the microenvironment in the phagosome should be attempted to 
improve the efficiency of the microbicidal activity of phagocytic cells.
8. Effective compliance enhancers or incentives should be identified and psycho­
metric and other tests should be developed to identify persons for whom various 
enhancers are likely to be most effective.
Improving Methods for Diagnosing Disease
Current techniques for diagnosing tuberculosis are beset by a number of serious 
limitations and problems. Available techniques are slow, resource intensive, and not 
ideally sensitive and specific.
One objective of this program is to develop better diagnostic techniques that will 
rapidly identify persons with current disease and distinguish them from persons with 
past disease or infection without disease.
Improving Methods for Treating Disease
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Methods
1. High priority should be placed on the search for genus- and species-specific 
epitopes.
2. DNA probes specific for M. tuberculosis should be produced and evaluated.
3. Similarly, genus- and species-specific monoclonal antibodies should be produced 
and evaluated for their ability to rapidly detect and identify M. tuberculosis and 
other medically significant mycobacteria.
4. Studies to detect free mycobacterial antigens with appropriate antibodies or 
probes in clinical specimens should be undertaken.
5. Systems that would assay material produced by the diseased host's lymphocytes 
or macrophages might be useful for diagnosis. A related area to be explored is 
the study of the T-lymphocyte antigen receptor.
Conclusion
There is an urgent need for competent investigators to submit well-designed 
proposals for all of the above studies. CDC should oontinue to work with the National 
Institutes of Health, the Food and Drug Administration, state and local health 
departments, private industry, academia, volunteer agencies, foundations, and other 
groups to encourage the funding and conducting of this research. A report from 
federal and private research funding agencies should be submitted annually to the 
Secretary's Advisory Committee for Elimination of Tuberculosis detailing progress 
made in achieving these research objectives.
STEP 3 -  TECHNOLOGY ASSESSMENT AND TRANSFER
This step of the elimination plan focuses on the actions necessary to facilitate the 
adoption of new tools, procedures, and ideas into clinical and public health practice. 
(This has been called technology transfer or translation.) Because we are generally 
discussing the assessment and transfer of technologies not yet developed, it is not 
possible to be as specific in this section as in the preceding two sections.
Technology Assessment and Transfer in General
Impediments to the technology and assessment transfer process must be identi­
fied and strategies devised to resolve them. Problems arise if the new technology 
requires retraining, additional resources, or a change in habits. Problems also arise if 
cost-effectiveness data on a new technology are not available or if cost savings from 
a new procedure do not accrue to those who spend the resources to adopt the new 
technology.
It is important to ensure the widespread, rapid, and efficient use of new technol­
ogies for tuberculosis control in field operations.
Methods
Technologies for transfer should be chosen on the basis of their potential impact 
on the tuberculosis-elimination effort. Before a program is initiated to "sell" a new 
technology, it is crucial to develop a consensus on its appropriateness, identify 
persons who will be using the new technology, enlist their aid, identify potential
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resistance points to the introduction of new technologies and innovations, and 
develop strategies for overcoming the resistance.
Methods to be used in specific sectors are as follows:
1. The Federal Sector
a. Lead responsibility for setting standards for technology transfer should rest 
with CDC through its ongoing work with the American Thoracic Society's 
Scientific Assembly on Microbiology, Tuberculosis, and Pulmonary Infection; 
the American Academy of Pediatrics "Redbook" Committee; and other expert 
groups. These groups should critically assess information about new technol­
ogies and make recommendations about further evaluation and implementa­
tion.
b. The involvement of other federal agencies (including the National Institutes of 
Health, the Food and Drug Administration, the Health Care Financing Admin­
istration, the Health Resources and Services Administration, the Veterans 
Administration, and the Immigration and Naturalization Service) on an Inter­
agency Task Force will be important in the technology assessment and transfer 
process.
c. CDC Public Health Advisors and their state and local counterparts should 
continue to translate national recommendations into local practice. Public 
Health Advisors should be assigned the tuberculosis control program of each 
state and big city requesting such assistance. These programs should be 
encouraged to develop their own program-management capacity to transfer 
new technology.
d. When available, federal grant funds should continue to be used as seed money 
for implementating new tuberculosis technology, demonstration projects, and 
technology assessments. States and localities should continue to fund ongoing 
community tuberculosis control efforts and eventually assume the cost of each 
new technology as its advantages become apparent.
e. CDC should explore with the Health Care Financing Administration the possi­
bility of Medicare and Medicaid reimbursement for tuberculosis control ser­
vices such as directly observed therapy, nursing services, translation services, 
transportation services, and halfway housing for tuberculosis patients. Re­
sources to provide these services to persons not covered by Medicare or 
Medicaid must also be sought.
f. CDC should continue to disseminate information about new technologies to as 
wide an audience as possible. Current vehicles for this information exchange 
include the Morbidity and Mortality Weekly Report, articles and editorials in 
peer-reviewed medical and nursing journals, training courses (such as "TB 
Today!"), and national tuberculosis conferences. These should be supple­
mented with new educational tools such as videotapes, satellite teleconferenc­
ing, computerized bulletin boards, and programmed instruction packages.
g. The Division of Tuberculosis Control, Center for Prevention Services, CDC, 
should continue to work with national organizations (e.g., the American 
Hospital Association, major health maintenance organizations, and nursing 
home organizations) to assist in establishing policies for tuberculosis control.
h. The mycobacteriology laboratory at CDC should continue to play an important 
role in the assessment and transfer of technology in the diagnostic and
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laboratory areas through premarketing and postmarketing evaluation of new 
technologies and scientific publications.
i. The Division of Quarantine, Center for Prevention Services, CDC, should apply 
new technology for controlling tuberculosis among immigrants, refugees, and 
other entrants.
2. The State and Local Public Sector
a. Technology-assessment and -transfer activities of state and local tuberculosis 
control programs should complement those of the federal sector. Strengthen­
ing state and local health department infrastructure (noted in Step 1) will 
enhance the implementation of new technologies.
b. The American Public Health Association, Association of State and Territorial 
Health Officials, the Council of State and Territorial Epidemiologists, the 
National Association of County Health Officers, the U.S. Conference of Local 
Health Officers, the Association of State and Territorial Public Health Nursing 
Directors, the Association of State and Territorial Laboratory Directors, state 
and local advisory committees, and other similar organizations can play a vital 
role by recommending the adoption of the elimination plan and new preven­
tion and control technologies.
c. State and locally funded evaluations of new technologies through demonstra­
tion programs will be important to their adoption locally.
d. Promulgation of information on new technologies through state and local 
public health newsletters can help to spread new technologies through the 
public sector and into the private sector as well.
e. This sector should link with the academic institutions to educate the private 
medical sector about new technologies in tuberculosis. This might involve 
making telephone calls or personal visits to physicians who report and/or 
manage cases and providing them with current literature.
3. The Volunteer Sector
a. Since the turn of the century, the American Lung Association has led our 
nation's efforts to establish effective public health programs to deal with the 
problem of tuberculosis. Continuation of these educational and advocacy 
activities, including support of local American Lung Association/American 
Thoracic Society educational activities, will be essential to the technology- 
transfer effort. To enhance its effectiveness, the American Lung Association 
should continue to form national, state, and local coalitions with other groups, 
such as the American Public Health Association and the American Academy of 
Pediatrics, to urge that resources be made available for eliminating tuberculo­
sis.
b. Advocacy groups representing populations with high rates of tuberculosis can 
play an important role in technology transfer when they are involved in 
decision-making and in the education of their constituents and health care 
providers who serve them.
c. Foundations can serve in technology assessment and transfer by providing 
funding for demonstration projects and educational programs.
4. Professional Medical Societies and the Private Medical Sector
a. Some medical specialty groups, such as the American Thoracic Society and the 
American College of Chest Physicians, have assisted in the transfer of new 
technology through the preparation and dissemination of authoritative state-
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merits on tuberculosis, educational programs, and consensus conferences. In 
the future, these and other professional groups (including the American 
Academy of Pediatrics, the American Medical Association, the National Medi­
cal Association, the American College of Physicians, the Infectious Diseases 
Society of America, the American Academy of Family Physicians, the American 
Osteopathic Association, the Society of Hospital Epidemiologists, the Associ­
ation of Practitioners of Infection Control, and the American Nurses Associa­
tion) should increase their educational efforts in tuberculosis and produce and 
distribute written, audio, and video programs on various new tuberculosis 
control techniques.
b. Selected physicians who are respected in their communities will serve as 
opinion leaders in technology transfer. Such persons must be sought out and 
their assistance requested for educational programs.
c. Health-maintenance organizations, occupational health clinics, hospitals, and 
other health-care groups can assist in technology transfer by holding seminars 
and conferences on new technologies in tuberculosis, incorporating new 
technology into routine patient-management protocols, and by distributing 
educational materials on tuberculosis to employees in their institutions.
d. Important audiences to reach with education messages are infection-control 
nurses, medical and nursing educators, medical and nursing students, and 
house staff. These groups must be mobilized for informed action in any 
elimination campaign.
5. The Business Sector
a. Health-insurance providers can assist in technology transfer by paying for 
treatment and prevention modalities shown to be cost effective. Otherwise, the 
higher costs of less effective treatments will be borne by the carrier. An 
example would be the provision of twice-weekly, directly observed therapy 
that prevents unnecessary hospitalization, drug resistance, and treatment 
failure.
b. Industry can serve a role in transferring new technology, especially when it 
anticipates a profit in the adoption of the technology. Industry might also fund 
demonstration projects, especially if a successful outcome would lead to 
increased use of the technology being investigated. Pharmaceutical companies 
have assumed the important role of sponsoring conferences and seminars.
6. The Media
a. Articles on advances in the diagnosis, treatment, and prevention of tuberculo­
sis should be published in newspapers and magazines to educate the general 
public, thereby increasing support for tuberculosis programs and increasing 
the demand for adoption of the new technology. Television news stories or 
public service announcements, billboards, and posters will serve the same 
function.
Special Technology Transfer Issues
This section concerns specific recommendations about methods and strategy for 
the transfer and implementation of specific new technologies that have been 
developed, but not adopted, or that are likely to be developed in the near future. The 
examples are divided into the same categories under which research efforts were 
outlined in Step 2 of this plan.
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Transferring Technologies for Preventing Disease in Infected Persons
1. Because the largest number of cases arise from the pool of persons infected in the 
past, highest priority must be given to the rapid evaluation and implementation 
of new technology in this area. It is likely that shorter (e.g., 2- or 3-month) 
preventive treatment regimens can be developed using currently available drugs.
2. To have a major impact on tuberculosis morbidity, newly developed short-course 
preventive therapy must be widely implemented by the private medical sector. 
This will require comprehensive education programs aimed at all physicians 
likely to see patients with tuberculosis. Professional organizations should assist in 
this effort. Increased emphasis on the prevention of tuberculosis in the curricula 
of medical schools and schools of public health should be undertaken. Cooper­
ative agreement, grant, or contract funds might be used to stimulate these 
educational efforts.
3. Health departments should begin now to develop registers containing the names 
and addresses of untreated infected persons so that they can be readily identified, 
contacted, and treated when improved prevention methods are available.
4. Public education is important for creating a demand for this service. Consumer 
groups and organizations representing populations experiencing high rates of 
tuberculosis should be involved.
Transferring Technologies for Defining Infected Persons at Risk o f Disease
New diagnostic tests will probably be developed in the near future. Before 
widespread adoption of the new tests, evaluation studies will be needed to determine 
whether they have significant advantages over the PPD-tuberculin skin test.
Transferring Technologies for Preventing Infection
A reduction in the number of tubercle bacilli in the environment may be achieved 
by the proper use of ultraviolet lights. Field studies of this technology in selected 
high-risk settings (e.g., hospital emergency rooms, correctional institutions, nursing 
homes, and shelters) should be undertaken as soon as possible.
Transferring New Technologies for Treating Disease
1. Recent experiences with the slow diffusion of short-course, directly observed, 
and intermittent therapy into clinical and public health practice suggest that new 
approaches will be required in the future to promote more rapid and widespread 
adoption of new treatments.
2. A strong recommendation for a new therapy from the American Thoracic Society 
and the Advisory Committee for Elimination of Tuberculosis will be essential. 
Demonstration projects in selected states and communities showing feasibility, 
patient acceptability, and improvement in program performance will speed 
acceptance of new approaches to treatment.
3. Federal support will be necessary for the wider application of new therapy 
regimens in the public sector. For the private sector, incorporation of instruction 
on new tuberculosis therapies into continuing medical education programs will 
be helpful. Such programs could be funded by pharmaceutical companies that 
market the drugs used in the recommended treatment regimens.
Transferring and Assessing New Technologies for Diagnosis o f Tuberculosis 
With the use of new DNA probes, it may soon be possible to make a specific 
diagnosis of tuberculosis in several hours. Before the use of these new diagnostic
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tests is recommended, they should be carefully assessed. Support for technology 
assessments might come from the commercial firm developing the product, other 
private groups, or the public sector.
Transfer of Communication Technologies
1. Improved communication is essential for transfer of state-of-the-art technology. 
The principal means by which this will be accomplished is frequent and timely 
telephone communication and on-line electronic transfer of information. It will be 
essential to develop and maintain an electronic network in which the public and 
private sector can submit and rapidly obtain current information about tubercu­
losis. CDC should standardize hardware and software requirements for this 
communication network and, to the extent possible, assist state and local health 
departments in obtaining hardware and software. The American Medical Asso­
ciation, the National Medical Association, and other professional groups should 
be approached regarding communication with the private sector.
2. Computerization of health department data bases will enhance the actions 
advocated in Step 1 of this plan.
Conclusion
Technology assessment and transfer in our society is a complex process involving 
many participants. Successful achievement will require federal coordination and 
some federal funding but will depend heavily on the active participation of state and 
local officials, private practitioners, private industry, and volunteer groups. The 
Advisory Committee can function as a focal point for these interactions.
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Appendix: Planning Assumptions
A. The public needs:
1. current and accurate information about tuberculosis and progress toward its 
elimination;
2. to be protected from infection with M. tuberculosis', and
3. if already infected, to be protected from disability and death from tuberculosis.
The public has a responsibility to:
1. insist that adequate resources be made available for tuberculosis control and 
that those resources be used efficiently and effectively.
B. Tuberculosis patients need:
1. quality diagnostic, preventive, and curative medical care that is available, 
accessible, and acceptable;
2. accurate and current information about the nature and risks of the disease and 
about the risks and benefits associated with treatment; and
3. confidentiality to the extent possible.
Tuberculosis patients have a responsibility to:
1. prevent transmission of their infection to others;
2. assist in the identification of contacts;
3. take medicine as prescribed and to cooperate with necessary clinical, radio- 
graphic, and sputum examinations; and
4. report problems with taking prescribed treatment, improvement or deteriora­
tion of symptoms, and symptoms suggestive of adverse drug effects.
C. Health-care providers need the following services from local health departments:
1. contact identification and evaluations;
2. regular follow-up of patients on treatment;
3. up-to-date patient-management guidelines and expert medical consultation; 
and
4. antituberculosis drugs, laboratory services, and directly observed therapy for 
their patients when needed.
Health-care providers have a responsibility to:
1. maintain a high index of suspicion for tuberculosis, especially for persons from 
high-risk populations;
2. report cases, suspected cases, and laboratory results to the health department 
within 72 hours;
3. treat patients and monitor their compliance and response to therapy, and 
monitor for adverse drug reactions within accepted medical guidelines;
4. promptly notify health departments when patients under their care do not take 
treatment as prescribed or do not return for necessary follow-up examina­
tions;
5. update health departments at specified intervals about current treatment 
(including degree of compliance), laboratory results, and disease status of 
each patient; and
6. cooperate with the health department in:
a. contact identification and examination;
b. the screening of other high-risk groups for infection and disease; and
c. the application of preventive therapy in those groups.
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D. State and local health departments need:
1. information from health-care providers to ensure that persons with diagnosed 
tuberculosis do not continue to spread the disease within the community and 
that persons with tuberculosis, suspected tuberculosis, or tuberculous infection 
are receiving appropriate examinations and treatment; and
2. the resources and authority to carry out their responsibilities.
State and local health departments have a responsibility to:
1. establish guidelines for the identification, reporting, treatment, and prevention 
of tuberculosis in the community;
2. ensure that patients with tuberculosis do not continue to transmit infection in 
the community;
3. provide rapid follow-up for persons diagnosed or suspected of having tuber­
culosis;
4. ensure that laboratory services, drugs, and the staff needed to provide 
follow-up, contact examination, and directly observed therapy are available;
5. ensure that high-risk groups, including those under the supervision of other 
state agencies (e.g., prisoners), are identified and screened for tuberculous 
infection and tuberculosis;
6. provide health education to the public;
7. appropriately use preventive therapy;
8. provide quality tuberculosis medical consultation for medical-care providers;
9. provide outpatient and inpatient medical care for tuberculosis at no cost to the 
patient when such care is not available from other sources;
10. rapidly transfer patient information from one jurisdiction to another when a 
patient moves;
11. establish and maintain a records system (register) that is effective for moni­
toring and evaluating the tuberculosis problem in the community; and
12. coordinate all state and local tuberculosis control activities.
E. The Federal Government needs:
1. the resources required to carry out its responsibilities; and
2. accurate and timely reports from state and local programs (e.g., case reports, 
reports of outbreaks).
The Federal Government has a responsiblity to:
1. establish goals and priorities and publicize guidelines and standards;
2. provide expert medical and program consultation, program evaluation, public 
health education and training, and national morbidity and mortality surveil­
lance;
3. conduct or support the basic and applied research studies, developmental 
work, demonstration projects, and technology assessments necessary for the 
development of new technologies for prevention and control;
4. ensure that aliens entering the United States are free of infectious or poten­
tially infectious tuberculosis;
5. supplement, as necessary, local and state resources to carry out the elimina­
tion plan set forth in this document;
6. publicize progress made toward the elimination of tuberculosis in the United 
States;
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7. assure that federal programs that provide direct or indirect clinical services to 
high-risk populations (e.g., Bureau of Prisons, Indian Health Service) appropri­
ately screen for and treat tuberculosis infections and tuberculosis; and
8. direct health-care providers to coordinate patient care with state and local 
public health authorities.
F. Academic centers need to:
1. compete fairly for federal, state, and foundation funds for tuberculosis educa­
tion and research projects.
Academic centers have a responsibility to:
1. provide high-quality educational and tuberculosis control programs for their 
students, staff, and affiliated hospitals;
2. provide high-quality care to tuberculosis patients; and
3. use grant and contract funds to carry out well-designed and well-executed 
research studies and disseminate the results.
G. Private enterprise needs:
1. adequate return for its investments in tuberculosis prevention and control.
Private enterprise has a responsibility to:
1. use its resources to develop more effective methods for prevention and control 
of tuberculosis.
H. The American Lung Association and other voluntary/professional agencies should
continue to:
1. be advocates for the appropriation of resources and the enactment of 
legislation to achieve elimination of tuberculosis;
2. support, and encourage the support of, medical research and pilot demonstra­
tion projects;
3. provide public, medical, and professional health-worker education;
4. participate in developing standards for prevention, diagnosis, and treatment; 
and
5. form coalitions with other organizations to achieve the above aims.
Finally, it is assumed that our society will continue to make progress in ensuring
that all citizens have access to adequate nutrition, housing, and medical care.
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